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Symmetrical Dose-Dependent DNA-Methylation Profiles
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Daniel De Carvalho,3,6 Rosanna Weksberg,2,7,8 and Lucy R. Osborne1,9,*
Epigenetic dysfunction has been implicated in a growing list of disorders that include cancer, neurodevelopmental disorders, and neuro-
degeneration. Williams syndrome (WS) and 7q11.23 duplication syndrome (Dup7) are rare neurodevelopmental disorders with broad
phenotypic spectra caused by deletion and duplication, respectively, of a 1.5-Mb region that includes several genes with a role in epige-
netic regulation. We have identified striking differences in DNAmethylation across the genome between blood cells from children with
WS or Dup7 and blood cells from typically developing (TD) children. Notably, regions that were differentially methylated in both WS
and Dup7 displayed a significant and symmetrical gene-dose-dependent effect, such that WS typically showed increased and Dup7
showed decreased DNA methylation. Differentially methylated genes were significantly enriched with genes in pathways involved in
neurodevelopment, autism spectrum disorder (ASD) candidate genes, and imprinted genes. Using alignment with ENCODE data, we
also found the differentially methylated regions to be enriched with CCCTC-binding factor (CTCF) binding sites. These findings suggest
that gene(s) within 7q11.23 alter DNA methylation at specific sites across the genome and result in dose-dependent DNA-methylation
profiles inWS andDup7. Given the extent of DNA-methylation changes and the potential impact onCTCF binding and chromatin regu-
lation, epigenetic mechanisms most likely contribute to the complex neurological phenotypes of WS and Dup7. Our findings highlight
the importance of DNAmethylation in the pathogenesis ofWS andDup7 and providemolecularmechanisms that are potentially shared
by WS, Dup7, and ASD.Introduction
Disorders that arise via deletion or duplication of the
same set of genes provide unique insight into the effects
of changes in gene dosage during development. Two
such disorders are Williams syndrome1 (WS [MIM:
194050]) and 7q11.23 duplication syndrome2 (Dup7
[MIM: 609757]), which are rare neurodevelopmental disor-
ders caused by deletion and duplication, respectively, of
25 genes in chromosomal region 7q11.23. Copy-number
variation (CNV) at this locus causes symmetrical alter-
ations in gene dosage and expression and results in distinct
but overlapping phenotypic spectra.
WS is associated with a recognizable facies, characteristic
cardiovascular lesions, and an array of medical problems.3
Individuals with WS usually have global cognitive impair-
ment but show relative strength in concrete vocabulary
and verbal short-termmemory; they also display moderate
to severe deficits in visuospatial construction.4 They often
exhibit social disinhibition and lack of usual social bound-
aries, but non-social anxiety is common.4,5 Dup7 has not
been as extensively characterized, but the emerging picture
is of a syndrome that is distinct from WS and invariably
associated with speech problems and language delay or
disorder. Anxiety, especially social phobia, is common.6
Neuropsychiatric phenotypes are common to both WS
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least one anxiety disorder.4,5 In addition, around 35% of
children with Dup7 and 65% of children with WS have
attention deficit hyperactivity disorder, and around 25%
are diagnosed with oppositional defiant disorder or other
disruptive behavior disorders.4–6 These complex neurode-
velopmental disorders also includebothcore andassociated
features of autism spectrumdisorder (ASD) and so provide a
unique window into genes and pathways that contribute
to symptoms of ASD. Features common to ASD, such as
speech disorder and repetitive behaviors, have been re-
ported in many individuals with Dup7,7,8 and 7q11.23
duplication has been independently identified as both
an ASD-associated CNV9,10 and a risk factor for schizo-
phrenia.11 We, and others, have reported that some socio-
communicative difficulties in children with WS signifi-
cantly overlap those in children with ASD,12–14 and some
children with WS have been classified as having ASD.12–17
Research efforts have investigated the molecular bases
for the complex neurological phenotypes of WS and
Dup7, but the potential impact of 7q11.23 rearrangements
on the epigenome has not been studied. Epigenetic
modifications can be tissue specific and extremely dy-
namic, and they play key roles in the development of the
mammalian nervous system.18 Of the 25 genes commonly
deleted or duplicated inWS or Dup7, respectively, six genes
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epigenetic mechanisms or complexes. Williams-Beuren
syndrome chromosome region 22 (WBSCR22) contains
an S-adenosyl-L-methionine binding domain typical of
methyltransferases andhasbeenassociatedwith chromatin
remodeling;19 NOP2/Sun domain family 5 (NSUN5) has
been shown to act as anRNAmethyltransferase;20 complete
loss of bromodomain adjacent to zinc finger domain 1B
(BAZ1B), a subunit of the WICH and B-WICH chromatin-
remodeling complexes, has been shown to affect hetero-
chromatin formation;21 and B cell CLL/lymphoma 7B
(BCL7B) has been identified as a mammalian SWI/SNF
ATP-dependent subunit of the chromatin-remodeling
complex.22 The general transcription factors GTF2I (also
known as TFII-I) and GTF2IRD1 have both been shown
to functionally interact with the histone deacetylase
HDAC3.23 Moreover, TFII-I in particular has been shown
to interact with numerous regulatory complexes, including
HDAC1, HDAC2, the lysine-specific demethylase 1 (LSD1)
complex, and components of the polycomb complex.24,25
Given the number of 7q11.23 genes that are associated
with epigenetic mechanisms and the importance of
epigenetic mechanisms during neurodevelopment, we
hypothesized that rearrangements of this locus would
alter the epigenome of children with WS and children
with Dup7. Disruptions of epigenetic mechanisms,
including chromatin remodeling and DNA methylation,
have been implicated in numerous neurodevelopmental
and neuropsychiatric disorders, including ASD26 and
schizophrenia.27 We compared the impact of gene dosage
at 7q11.23 on genome-wide DNA methylation between
whole-blood samples from children with WS or Dup7
and samples from age-matched typically developing (TD)
control children. We identified striking, genome-wide
dose-dependent changes in DNA methylation across the
WS and Dup7 groups, suggesting that aberrant DNA
methylation might be an important contributor to the
pathophysiology of these disorders.Subjects and Methods
Research Participants
All procedures were approved by the research ethics boards of the
University of Toronto and The Hospital for Sick Children, and
written informed consent was obtained from parents of all partic-
ipants. 7q11.23 deletion or duplication size was determined by
CNVmicroarray analysis and confirmed by real-time PCR analysis;
only children who had classic deletions or duplications were
included. Children were between 2.4 and 10.7 years of age at the
time of the blood draw. Descriptive statistics for the participants’
age at blood draw are presented in Table S1.DNA-Methylation Array Profiling
DNA was extracted from whole-blood samples with the QIAamp
DNA Blood Mini Kit (QIAGEN), the ArchivePure DNA Blood Kit
(5 PRIME), or the AllPrep DNA/RNA Mini Kit (QIAGEN). DNA
was then subject to sodium bisulfite treatment. In brief, 1 mg of
genomic DNA was converted with sodium bisulfite by the EpiTectThe AmerBisulfite Kit (QIAGEN) according to the manufacturer’s protocol.
Genome-wide DNA-methylation profiling was performed with
the Infinium HumanMethylation450 BeadChip Kit and arrays
(Illumina) by The Centre for Applied Genomics (The Hospital
for Sick Children, Toronto). Sodium-bisulfite-treated DNA was
hybridized onto the BeadChip with Illumina’s Infinium HD
Methylation protocol and scanned with Illumina’s iScan SQ
Scanner.Statistical Analysis
Image files were pre-processed with the Illumina GenomeStudio
(v.2011.1) Methylation Module (v.1.9.0) with background correc-
tion and Illumina-based normalization. Quality control was per-
formed in GenomeStudio and included assessing the efficiency
of sodium bisulfite conversion, extension, hybridization, and
labeling. With the use of the Illumina Methylation Analyzer
(IMA)28,29 and DMRcate30 packages in the R statistical environ-
ment, normalized data were further filtered for excluding poorly
performing probes, probes that mapped to sex chromosomes,
cross-reactive probes, and probes that overlapped SNPs with a
minor allele frequency (MAF) of R0.5 and fell at least 2 bp from
the end of the probe. Principal-component analysis (PCA) and
volcano plots were generated in the R statistical environment.
Logit-transformed beta values (M-values) were calculated in the
IMA and used for statistical modeling.
To account for potential differences in blood cell populations,
we approximated the cellular composition of each sample by
using an adjusted Houseman algorithm available in the minfi
package31 in the R statistical environment. We incorporated the
composition of granulocytes, CD8þ T cells, CD4þ T cells, B cells,
natural killer cells, and monocytes as covariates in a linear
regression model by using the limma package in R,32 and we
applied Benjamini-Hochberg correction to correct for multiple
testing.33 This analysis revealed significant differences in the esti-
mate of cellular composition between the three groups (Figure S1;
Table S2), although there is currently no clinical evidence to
suggest that either children with WS or children with Dup7
show differences in blood cell composition. It is therefore likely
that at least some of the detected differences are caused by
7q11.23 dose-dependent changes in DNA methylation at the CG
sites used for the analysis.
We used Kruskal-Wallis with Dunn’s post hoc test when
comparing DMP methylation levels between the three cohorts as
a measure of the significance of genotype. Each probe had been
previously identified as significantly differentially methylated
(DM) in relation to probes from TD control children.
Many probes were identified as significantly DM and clustered
together, suggesting the presence of a DM region (DMR). To test
for this, we performed DMR analysis by using the R package
DMRcate.30 We incorporated the same limma model we used to
identifyDMpositions (DMPs) into this analysis andused estimated
blood cell counts as covariates in the linear model. We used the
default DMRcate settings: a lamda of 1,000, scaling factor of 2,
Benjamini-Hochberg correction for multiple testing, and p value
cutoff of 0.05. Significant DMRs were retained if they contained
two or more probes and the maximum change in methylation
was >10%. A list of significant DMRs can be found in Table S3.Pyroseqencing Validation
Sodium bisulfite pyrosequencing analysis was performed on
selected DMRs according to a method described previously.34ican Journal of Human Genetics 97, 216–227, August 6, 2015 217
Primers were designed with PyroMark Assay Design Software
(QIAGEN) to target at least oneDMCpG, and sodium-bisulfite-con-
verted DNA remaining from samples previously hybridized to the
array were used. Amplicons were analyzed with a PyroMark Q24
pyrosequencer (QIAGEN), andmethylation levels (%)were quanti-
fied with PyroMark Q24 Software (QIAGEN). A list of the primer
sequences from the pyrosequencing assay is shown in Table S4.
Expression Analysis
RNA was extracted from whole blood collected in Tempus Blood
Collection Tubes (Life Technologies) with the QiaAmp RNA Blood
Mini Kit (QIAGEN) according to the manufacturer’s protocol.
500 ng of RNAwas converted to cDNAwith Superscript III Reverse
Transcriptase (Life Technologies) and the addition of a final RNase
H (Life Technologies) treatment. In preparation for real-time PCR,
cDNA samples were diluted at 1:100 in nuclease-free water. Real-
time PCR was performed with Power SYBR Green PCR Master
Mix (Life Technologies) and assessed with the ViiA 7 detection
system (Life Technologies). Standard curves were generated for
each primer set, and detected values were normalized to the
housekeeping genes HPRT1 and TBP. Primer sequences from the
real-time PCR assay are shown in Table S5.
GO Enrichment Analysis
For accounting for differences in the number of probes per gene,
GO enrichment analysis was performed with Genomic Regions
Enrichment of Annotations35 with the single-nearest-gene associ-
ation setting. All array probes that were retained after filtering
were used as a background dataset.
ENCODE Analysis
ENCODE datasets36 were retrieved and filtered to exclude peaks
containing hotspots (1,628 ENCODE peaks included). Intersec-
tions of DM CpGs from each group (WS CpGs hyper- or hypome-
thylated and Dup7 CpGs hyper- or hypomethylated in relation
to control CpGs) and ENCODE peaks were calculated with 1,000
permutations. Enrichment p values were calculated with the
R function pnorm. Enrichment Z scores were calculated for the
50 most significant enrichments.
Enrichment Analysis of the Transcription Factor Motif
Probes were ranked on the basis of decreasing differential methyl-
ation (delta-beta cutoff ¼ 10%, p < 0.05), and the sequence flank-
ing 100 bp around the CG probe was obtained (201 bp). For
identifying significantly enriched transcription factor motifs, the
ranked sequences were tested with Analysis of Motif Enrichment
(AME)37 in theMEME suite; the rank-sum test was used for enrich-
ment, and sequences were tested against JASPAR CORE Vertebrata.
Enrichment analysis of known motifs was performed with AME
with the same statistical parameters. Sequences containing
specific motifs were identified with Find Individual Motif Occur-
rences (FIMO)38 under the default settings.Results
Genome-wide, Symmetrical DNA-Methylation
Differences in Children with WS and Children
with Dup7
In this study, we assessed genome-wide DNA methylation
in whole blood from 20 children with WS, 10 children218 The American Journal of Human Genetics 97, 216–227, August 6with Dup7, and 15 TD children by using the Infinium Hu-
manMethylation450 BeadChip array (Illumina). After
removal of cross-reactive and SNP-containing probes and
adjustment for blood cell composition, PCA revealed
distinct differences in DNAmethylation between the three
groups, such that theWS cohort showed amore significant
difference in DNA-methylation profiles than the Dup7
cohort (Figure 1A). Comparing each case cohort to TD
control individuals, we identified 1,413 CG probes that
were significantly DM between WS and TD and 508 CG
probes that were DM between Dup7 and TD by using a
methylation-difference delta-beta cutoff of 10% and a
Benjamini-Hochberg-adjusted p% 0.05 (Figure 1B). Using
the same cutoff, comparison between the WS and Dup7
cohorts identified 5,453 DMPs (Figure 1B), the vast
majority of which showed dose-dependent methylation
changes.
DMPs were found genome-wide, and there was no spe-
cific chromosomal enrichment (Figure S2). Comparison
of the DMPs within each cohort revealed 147 probes that
were significantly DM between TD control individuals
and both WS and Dup7 groups (Figure 1B), and hierarchi-
cal clustering of these probes revealed a distinct gene-dose-
dependent response, such that the WS-affected children
showed more gain of methylation and the Dup7-affected
children showed more loss of methylation than did con-
trol children (Figure 1C). Only one of these probes,
cg19313311, fell within the 7q11.23 CNV. Most of these
probes that were DM in children withWS showed symmet-
rical methylation patterns in Dup7. Importantly, the
methylation levels across these 147 probes were sufficient
for correctly clustering each individual within his or her
correct genotypic cohort (Figure 1C). These 147 DMPs
corresponded to 56 unique genes, 3 pseudogenes, and 1
long non-coding RNA (Table S6). Many probes were not
significantly DM by>10% between TD control individuals
and each cohort, but they were significantly DM by >10%
between the WS and Dup7 groups.
Dose-Dependent Changes in DNA Methylation across
Genes Important for Brain Development and Function
The majority of genes associated with DMPs were not
expressed in our starting tissue—whole blood—but were
expressed in other tissues, particularly in the developing
or adult brain (DMPs are listed in Table S7). One of
the most DM genes was ankyrin repeat domain 30B
(ANKRD30B), which showed striking dose-dependent
DNA-methylation changes spanning 11 different probes
across the promoter (Figure 2A). Found only in primates,
ANKRD30B is expressed in the brain, breast, and testis,
but its function is unknown.39 Consistent dose-dependent
differential methylation was also observed across the pro-
moter region of ret finger protein-like 2 (RFPL2 [MIM:
605969]; Figure 2B), a member of the primate-specific
chromosome 22 RFPL cluster, which shows high expres-
sion during the onset of neurogenesis and within the
developing neocortex and has been linked to primate, 2015
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Figure 1. Differential Genome-wide DNA Methylation between TD Children and WS- and Dup7-Affected Children
WS and Dup7 cohorts can be distinguished from the TD control group and from each other on the basis of genome-wide DNA
methylation.
(A) PCA revealed three distinct groups, corresponding to children with WS (blue), TD control children (gray), and children with Dup7
(green).
(B) AVenn diagram shows the total number of DMPs between WS and TD groups, between Dup7 and TD groups, and between WS and
Dup7 groups. Analysis of differential methylation in each cohort resulted in 1,413 DMPs between WS and TD groups, 508 DMPs be-
tween Dup7 and TD groups, and 5,453 DMPs between WS and Dup7 groups (adjusted p % 0.05, delta-beta R 10%). Comparison of
the WS and Dup7 datasets to the TD control dataset resulted in 147 sites sharing significant differential methylation.
(C) A heatmap shows methylation changes for all 147 overlapping DMPs, all of which showed dose-dependent changes in DNA
methylation.cortical evolution.40We saw 282 DMPs spanning the entire
protocadherin (PCDH) cluster in chromosomal region
5q31.3 (Figure 3A). The PCDHs are homophillic cell-adhe-
sion proteins present predominantly in the developing
brain and confer single-cell neuron identity.41 We also
saw changes in DNA methylation outside promoter re-
gions, such as at probe cg05374271, found in an active
transcription start site of the regulator of G protein
signaling RGS2 (MIM: 600861), which has been previously
associated with anxiety,42 panic disorder,43 and schizo-
phrenia44 (Figure S3A). HDAC4 (MIM: 605314), an ASD
candidate gene,45 also showed altered DNA methylation
(Figure S3C). Differential methylation across ANKRD30B,
RFPL2, and RGS2 was confirmed by pyrosequencing
(Figure S4), and real-time PCR analysis of RGS2 and
HDAC4, two of only a few DM genes expressed in
blood, demonstrated that changes in methylation wereThe Amerassociated with reduced gene expression in the WS group
(Figures S3B and S3D). Additional dosage-sensitive genes
of interest include the neuronal migration gene NTN1
(MIM: 60161446; Figure 2C) and PRDM9 (MIM: 609760;
Figure 2D), which encodes a histone methyltransferase
that activates recombination hotspots during meiosis47
and is rapidly evolving in primates.48
Some genes were significantly DM between TD control
individuals and only one affected group, but we observed
a non-significant trend in the other group. For example,
MKRN3 (MIM: 603856) and NDN (MIM: 602117), both of
which lie within 15q11–13, the imprinted region associ-
ated with Prader-Willi (MIM: 176270) and Angelman
(MIM: 105830) syndromes49 (Figure S5A), were DM in
the Dup7 group (decreased methylation) and showed a
trend toward increased methylation in the WS group (Fig-
ures S5B and S5C). Many other probes within 15q11–13ican Journal of Human Genetics 97, 216–227, August 6, 2015 219
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Figure 2. Dose-Dependent DMRs in WS- and Dup7-Affected Children
Scatter plots fitted with Loess curves depict dose-dependent DNA-methylation changes between the WS (blue), Dup7 (green), and TD
(gray) groups. Methylation levels for each sample are shown on the basis of the position of each CG probe within the gene. A schematic
of the gene and the corresponding CG probes are shown below each graph.
(A) A dose-dependent DMR was observed across 14 CpG sites in ANKRD30B (mean DMR p ¼ 1.13e28).
(B) Two DMRs spanning nine CpG sites within the promoter region of RFPL2 (mean DMR p¼ 6.64e9 at chr22: 32,598,479–32,599,648
and p ¼ 3.06e35 at chr22: 32,600,722–32,601,654).
(C) One DMR spanning eight CpG sites within the promoter region of NTN1 (mean DMR p ¼ 2.94e3).
(D) One DMR spanning nine CpG sites within the promoter region of PRDM9 (mean DMR p ¼ 3.10e76).were symmetrically DM in the WS and Dup7 cohorts but
did not meet statistical significance or were not DM by a
minimum of 10% between the affected cohorts and the
TD control group (Figure S5A). DMR analysis identified
all of the above genes as containing significant DMRs,
which were represented by the individually significant
DMPs (Table S3).
Cohort-Specific Changes in DNA Methylation
A few loci showed altered DNA methylation in either the
WS or the Dup7 cohort, but not in both groups. For
example, the imprinted homeobox 4A (HOXA4 [MIM:
142953])50 showed consistent hypermethylation only in
the WS group, but the methylation levels in the Dup7220 The American Journal of Human Genetics 97, 216–227, August 6group were indistinguishable from those in the TD control
group (Figure S6A). In contrast, HOXB7 (MIM: 142962)
showed hypomethylation in the Dup7 group, but no sig-
nificant increase in methylation was seen in the WS group
(Figure S6B).
GO Enrichment in WS and Dup7 DM Gene Sets
Given that many DM genes were related to neurodevelop-
ment, we assessed whether the DM genes were enriched
with specific Gene Ontology (GO) terms. Using stringent
assessment parameters that correct for differences in the
number of probes per gene on this array, we observed
that the genes hypermethylated in the WS group showed
significant enrichment of GO terms relating to cell, 2015
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Figure 3. Dose-Dependent DNA-Methylation Changes Spanning the PCDH Cluster
(A) Epigenetic information spanning the PCDH cluster shows a total of 282 significant DMPs between theWS group (blue) and the Dup7
group (green). TheWS group had 105 significant DMPs, of which 60 were DM by >10% in comparison to the TD group, and all showed
hypermethylation in relation to the TD group. The Dup7 group contained 30 significant DMPs, of which 4 had a loss of methylation
of >10% in relation to the TD group.
(B) Methylation levels of probe cg18029321 (within PCDHA9) showed a 18.5% gain of methylation in the WS group (blue; adjusted
p ¼ 0.002) and a 20% loss of methylation in the Dup7 group (green; adjusted p ¼ 0.018) in relation to the TD group (gray).
(C) Methylation levels of probe cg24811352 (within PCDHB6) showed a 11.2% gain of methylation in the WS group (blue; adjusted
p ¼ 0.009) and a 10.9% loss of methylation in the Dup7 group (green; adjusted p ¼ 9.08e4) in relation to the TD group (gray).
(D) Methylation levels of probe cg11830096 (within PCDHGC4) showed a 11.6% gain of methylation in the WS group (blue; adjusted
p ¼ 0.03) and a 13.2% loss of methylation in the Dup7 group (green; adjusted p ¼ 3.15e2) in relation to the TD group (gray). Signif-
icance of the genotype effect was measured by the Kruskal-Wallis test: *p < 0.05, **p < 0.01, ***p < 0.001.adhesion (Figure 4A), synapse assembly (p ¼ 9.14e5),
synapse organization (p ¼ 3.10e2), and synaptic trans-
mission (p ¼ 1.89e3) (Table S8A), suggesting that aber-
rant DNA methylation might alter the expression of genes
important to synapse biology, a system consistently linked
with neurodevelopmental disorders, particularly ASD.45
Hypomethylated WS-associated genes were enriched with
terms relating to cytokinesis (Figure 4A). In comparison,
hypermethylated Dup7-associated genes were enriched
with GO terms relating to immunoglobulin isotype
switching, regulation of Cdc42, and regulation of STAT1
(Figure 4B), whereas hypomethylated genes within the
Dup7 cohort showed enrichment of terms relating not
only to meiosis and glial cell migration (Figure 4B) but
also to axonal fasciation (p ¼ 1.75e4), neuron recogni-
tion (p ¼ 6.95e3), and axon extension (p ¼ 1.18e3)
(Table S8C). The WS-versus-Dup7 dataset showed enrich-
ment of multiple terms relevant to brain development
and function (Figure 4C; Table S8E). A list of all enriched
terms identified can be found in Table S8.The AmerWS and Dup7 DM Gene Set Is Enriched with
ASD-Associated and Imprinted Genes
Given the associations between pathway enrichments and
specific DM genes and neurodevelopment and ASD, as well
as the phenotypic features of WS and Dup7, we assessed
the overlap between our DM gene set and known ASD
candidate genes from SFARI Gene. We found significant
enrichment of ASD candidate genes, such that there were
47 known ASD candidates in the symmetrically DM set
(hypergeometric p ¼ 3.37e5; Figure 4D). These included
13 high-confidence ASD-associated genes ranked by SFARI
as having the strongest possible evidence of involvement
in ASD (categories 1S and 2S in Table S9). Examples
included HDAC4 (three DM probes), SHANK2 (MIM:
603290; three DM probes), DYRK1A (MIM: 600855; two
DM probes), SHANK3 (MIM: 606230; one DM probe),
NRXN1 (MIM: 600565; one DM probe), CNTNAP2 (MIM:
604569; one DM probe), and ANKRD11 (MIM: 611192;
one DM probe). The remaining candidates were ranked as
having lower confidence by SFARI but still had supportingican Journal of Human Genetics 97, 216–227, August 6, 2015 221
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Figure 4. Analysis of GO Terms and ASD and Imprinted Gene Sets Reveals Enrichment of Neuronal Functions and CTCF Binding Sites
(A) GO enrichment analysis of WS hypermethylated DMPs (right, blue) and WS hypomethylated DMPs (left, blue).
(B) GO enrichment analysis of Dup7 hypermethylated DMPs (right, green) and Dup7 hypomethylated DMPs (left, green) identified
enrichment in diverse functions.
(C) GO enrichment analysis of DMPs between the WS and Dup7 groups.
(D) Comparative analysis of the symmetrically DM genes between the WS and Dup7 groups and known ASD candidate genes identified
47 shared genes (hypergeometric p ¼ 3.367e5).
(E) Comparative analysis of the symmetrically DM genes between the WS and Dup7 groups and imprinted and provisionally imprinted
genes (n ¼ 204) identified 36 genes (hypergeometric p ¼ 4.867e3). When the analysis was restricted to firmly established imprinted
genes (n ¼ 97), 19 genes were identified (hypergeometric p ¼ 2.510e3).evidence of involvement in ASD. These included EIF4E
(MIM: 133440; nine DM probes; Figure S7A), DPP6 (MIM:
126141; eight DM probes; Figure S7B), DLGAP2 (MIM:
605438; four DM probes), NRXN2 (MIM: 600566; two
DM probes), NRXN3 (MIM: 600567; two DM probes),
OXTR (MIM: 167055; two DM probes), and NLGN1
(MIM: 600568; one DM probe). A list of all enriched ASD-
associated genes can be found in Table S9.
We also saw enrichment of imprinted genes in our
DM gene set when we used either a list that included pre-
dicted imprinted genes, such as HOXA4 (hypergeometric
p ¼ 4.867e3), or a set that included only validated
imprinted genes (hypergeometric p ¼ 2.51e3) (Figure 4E;
Table S10).
ENCODE Enrichment Analysis of DM Probes
In addition to the DMRs that were associated with specific
genes, 28%–46% of DMPs mapped within non-genic
loci, particularly those in the WS hypermethylated and
Dup7 hypomethylated datasets (Figure S8). Enrichment
analysis using ENCODE datasets36 identified significant
dose-dependent enrichment of H3K9me3 and of regions
binding CCCTC-binding factor (CTCF) across multiple
different cell lines (Figure S9), suggesting an enrichment
of long-range regulatory elements.51222 The American Journal of Human Genetics 97, 216–227, August 6When focusing on a cell line that more closely resem-
bles that of our whole-blood DNA source (human B
lymphocyte cell line GM12878), we again identified high-
ly significant dose-dependent enrichment of H3K9me3,
CTCF, and members of the cohesion complex within
hypermethylated probes in WS and hypomethylated
probes in Dup7 (Figure 5A). Hypermethylated probes
within the Dup7 cohort and hypomethylated probes
within the WS cohort revealed enrichment of different
regulatory elements, including IKZF1, an important tran-
scriptional regulator of hematopoiesis,52 and H3K27me3,
a repressive chromatin mark important in cellular
differentiation and lineage specification53 (Figure 5B).
We again saw enrichment of CTCF but only within the
WS hypomethylated probes (Figure 5B). When focusing
on a human embryonic stem cell line (H1-hESC), we
observed even greater enrichment of H3K9me3 and
CTCF and of additional transcription factors and histone
marks (Figure S10). We again detected enrichment of
H3K27me3 within the WS hypomethylated probe set
and also detected dose-dependent enrichment of the
methyltransferase EZH2, which is responsible for the
methylation of H3K2754 (Figure S10). We observed con-
sistent results when we tested the DMPs in the WS and
Dup7 datasets (data not shown)., 2015
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Figure 5. Enrichment Analysis Using ENCODE Data Identifies Significant Dose-Dependent Enrichment of CTCF Binding Sites
(A) DMP enrichment analysis using ENCODE data from the human B lymphocyte cell line GM12878 revealed a dose-dependent enrich-
ment of the H3K9me3 histone mark and the CTCF and Rad21 binding sites (WS hypermethylated, blue, right; Dup7 hypomethylated,
green, left). WS hypermethylated probes also showed enrichment of binding sites for SMC3, a cohesion-complex member that is often
found in association with CTCF and Rad21.
(B) Dose-dependent enrichment of the transcriptional regulator IKZF1 binding site, the H3K27me3 and H3K4me1 histone marks, and
the Pol3 binding site was identified in WS hypomethylated probes (left, blue) and Dup7 hypermethylated probes (right, green). CTCF
and Rad21 binding sites were also enriched, but only in the WS hypomethylated probes.In concordance with our findings from the ENCODE da-
tasets, we also saw enrichment of CTCF binding consensus
sequences within the WS hypermethylated dataset when
we used AME (Table S11). Using this tool, we also found
enrichment of other transcription factor binding sites,
such as those for the early growth response transcription
factors EGR1 and EGR2, which have been associated with
neuronal plasticity55 and myelination,56 and those for
FOXP1 and FOXP2, both of which have been associated
with developmental speech disorders and/or ID57 (Table
S12). Because three transcription factors are contained
within the common 7q11.23 deletion and duplication,
we investigated whether their putative consensus se-
quences were enriched in our datasets. We observed signif-
icant enrichment of motifs associated with TFII-I58 and
GTF2IRD159 binding in WS hypermethylated probes and
in Dup7 hyper- and hypomethylated probes, and we also
observed enrichment of the MLXIPL binding ChORE
motif,60 but only in the WS hypermethylated dataset
(Table S12). GO enrichment analysis using DM genes inde-
pendently identified a TFII-I consensus sequence within
the symmetrically opposite gene set (WS versus Dup7;
Table S11).Discussion
We have identified striking gene-dose-dependent DNA-
methylation differences in two symmetrical CNVs. The
vast majority of DMPs showed symmetrical changes in
DNA methylation between the WS and Dup7 groups,
although both the total number of DMPs and the degree
of differential methylation appeared greater in the WS
cohort, suggesting that loss of 7q11.23 has a more pro-
found effect on DNA methylation than gain of the same
region. Dose-dependent transcriptional dysregulation
was recently identified in WS and Dup7 human induced
pluripotent stem cells (iPSCs),61 but we found manyThe Amermore dose-dependent changes in DNA methylation, and
in fact our stringent adjustment of the data for cell compo-
sition most likely excluded even more significant DMPs.
Aberrant DNA methylation has been implicated in
numerous neurological disorders, particularly ASD26 and
schizophrenia,27 and in WS- and Dup7-affected children,
we identified aberrant DNA methylation spanning many
genes and loci implicated in brain development or psychi-
atric disorders. Genes that were symmetrically DM were
enriched with biological processes relevant to the develop-
ment and function of the nervous system and were
enriched with ASD candidate genes. At this point, we do
not know whether these changes will be conserved in
other cell types, specifically neurons, but if changes in
DNA methylation occur very early in development, they
could be present in all tissues. Analyses of genome-wide
DNA methylation in iPSC-derived neurons would go
some way toward addressing this question.
The altered DNAmethylation identified across regions of
tightly regulated transcriptional control, such as the PCDH
cluster and the 15q11–13 region, is particularly intriguing.
PCDH genes have a unique mode of regulation where
allele-specific alternative splicing is controlled by DNA
methylation across transcript-specific promoters.62 It has
been hypothesized that this mode of regulation facilitates
the unique and combinatorial patterns of PCDHs on the
neuronal cell surface and thus leads to patterns of cell
identity in neurons of the developing brain.41 Previous
studies showed that DNA methylation across this locus,
as well as CTCF and cohesion binding,63,64 regulates
the monoallelic and combinatorial expression of specific
PCDH isoforms,65 and genetic variation across the locus
has previously been associated with ASD,66 ID,67 schizo-
phrenia, and bipolar disorder.68
CNVs within 15q11–13, the imprinted region associated
with Prader-Willi and Angelman syndromes, have also
been associated with autism69 and schizophrenia,70 and
epigenetic dysregulation of the normally biallelicallyican Journal of Human Genetics 97, 216–227, August 6, 2015 223
expressed GABAA receptors within this locus has been
identified in ASD.71 In our DM gene set, the enrichment
of imprinted genes, including MKRN3 and NDN at
15q11–13, suggests that CNVs at 7q11.23 affect either
the erasure or the re-establishment of the genomic imprint
after fertilization.72
Given the degree of differential methylation we
observed in children with WS and children with Dup7, it
is likely that one or more genes within 7q11.23 is actively
involved in the targeting or regulation of DNA methyl-
ation at specific genomic regions. TFII-I has recently been
shown to associate with DNA methyltransferase 3-like
(DNMT3L),73 suggesting that it might be involved in tar-
geting DNMT3L to specific genomic locations, thereby
increasing the catalytic activity of the active methyltrans-
ferases DNMT3A and DNMT3B at those sites.74 A separate
study also identified an interaction between TFII-I and
DNMT3B in iPSCs.61 Interestingly, both the PCDH cluster
and DPP6 were shown to undergo DNMT3B-mediated
methylation,75,76 and so it is possible that gene dosage of
GTF2I might be involved in the DM profiles we detected
at these loci. TFII-I has also been shown to bind to the
promoter region of EZH2, encoding a member of the poly-
comb repressive complex 2 (PRC2), in embryonic stem
cells,77 which is the same cell type in which we observed
enrichment of EZH2 binding sites and regions containing
H3K27me3-marked chromatin, a characteristic of tran-
scriptional silencing by PRC2, within DM probes.
TFII-I was recently identified as a novel binding partner
of CTCF, and this interaction was required for the targeting
of CTCF to specific genomic regions in cancer cell lines.78
We observed highly significant enrichment of DMPs over
CTCF binding sites in many different cell types, suggesting
that these regions are susceptible to aberrant DNAmethyl-
ation inWS and Dup7 in either a direct or indirect manner.
CTCF has been implicated in chromosome looping, mono-
allelic gene expression, and the regulation of developmen-
tally restricted or lineage-specific genes, making it a key
regulator of the genome.51 Notably, CTCF binding is
sensitive to DNA-methylation levels, suggesting that the
aberrant DNA methylation identified in WS and Dup7
could affect CTCF-based regulation. Given the associations
with TFII-I and various epigenetic regulators, this protein is
an attractive candidate for mediating at least some of
the DNA-methylation changes we observed in children
with WS and children with Dup7, although other genes
at 7q11.23 could be involved. Further studies are required
to fully elucidate which gene or combination of genes
within 7q11.23 is responsible for the dose-dependent
DNA-methylation changes observed in WS and Dup7.
Although our research focused on neuropsychiatric
phenotypes, some DM genes might contribute to other
symptoms seen in WS or Dup7. Hypertension is common
in WS, but not all the risk can be attributed to deletion
of ELN or copy number of the modifying NCF1.3 RGS2,
which was DM and showed decreased expression in the
WS group, has been linked to vascular remodeling224 The American Journal of Human Genetics 97, 216–227, August 6and hypertension, given that RGS2 levels correlate
inversely with blood pressure.79 It is therefore possible
that altered methylation and subsequent expression of
RGS2 contribute to hypertension in WS. The promoter of
HOX4A, which showed increased methylation only in
the WS group, has been shown to become hypermethy-
lated in hematopoietic cancers, particularly those arising
from the B cell lineage.80 Several cases of B cell lymphoma
have recently been reported in WS,81 and changes in the
regulation ofHOXA4 could be a contributing factor to their
pathogenesis or prognosis. Early puberty is also seen
in WS,3 and mutations in MKRN3, which is in the region
associated with Prader-Willi and Angelman syndromes,
have been associated with precocious puberty.82
In conclusion, we report evidence of genome-wide,
symmetrical, and dose-dependent changes in DNA
methylation in reciprocal deletion (WS) and duplication
(Dup7) syndromes. The DM genes were enriched with
those involved in neurological development, function,
and disease, even though the analysis was performed on
whole-blood DNA. Our data suggest that altered DNA
methylation might affect neurodevelopment in WS and
Dup7 and contribute to their distinct phenotypic expres-
sion, particularly features of ASD. Identification of the
specific 7q11.23 genes in which mutations cause altered
DNA methylation will improve our understanding of
the relationship and dynamics between chromatin remod-
eling and DNA methylation not only in relation to the
7q11.23 region but also throughout the genome. Further
analyses in individuals with WS and individuals with
Dup7 could reveal identifiable epigenomic signatures
that will give insight into the pathobiology of these
disorders (and perhaps similar neurodevelopmental disor-
ders) and could lead to improvements in prognosis and
treatments.Accession Numbers
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